Libyan tribesmen say they have closed El Shahara and El Feel oilfields    Egy Lease to provide finances of EGP1bln during 2020    Dozens wounded as security forces, protesters clash in Beirut    Harry, Meghan drop their royal titles repay £2.4 mln    International Film Music Contest accepts entries from a variety of composers, performers    Iran may review cooperation with IAEA if EU pressure mounts: TV    Russia's Putin says he opposes unlimited presidential term    Live score: Liverpool v Manchester United (Egyptian Premier League)    West Ham fan protest is familiar ground for Moyes    Tennis: Djokovic the man to beat, again, at Melbourne Park    Libya summit calls for all parties to refrain from oil hostilities    Honeywell, Etisalat Misr join forces to support Egypt's Smart City vision    Sisi, World Bank seeks further cooperation    Draft deal on Ethiopia's GERD to take shape this week    Egypt's Sisi praises Armed Forces' security, development efforts    Jaz Hotel Group to add 4 branches to its management in Q1 2020 with investments of EGP2.5bn: CEO    Iran's Khamenei should be careful with his words: warns Trump    S. Korean companies keen on new industrial partnerships with Egyptian counterparts: Ambassador    Parliamentary elections to be held in November: Baha Abu Shoqa    No pressures imposed on Egypt to accept Washington's deal on GERD: Irrigation Ministry    Egypt's young pharaoh, TUT in Australia's Boston exhibition    Al-Sisi heads to Berlin for Libya's peace talks    Nine arrested for smuggling foreign currencies: ACA    EgyptAir receives eighth A220-300 plane    Alexandria, Dekheila ports working normally despite medium rain    Iran's Khamenei stands by Guards after unrest over downed plane    Egypt's interior ministry says Mostafa Kassem received fair trial, was convicted terrorist    Screenwriter and producer Mohamed Hefzy's 'Ras El-Sana' to hit Egyptian cinemas in February    Egyptian actress Magda Al-Sabahi dies at 89    Egypt is best tourism destination for 2020 according to BBC    Government launches Upper Egypt's first cultural festival    GERD filling will consider Blue Nile hydrological conditions, potential impact on downstream reservoirs: Egypt, Ethiopia, Sudan, US and WB    Egypt names executive head of comprehensive health insurance authority – ministry    New study finds Ocean acidification does not affect behaviour of coral reef fish    Nancy Ajram's husband charged with ‘intentional' murder    6th of October Rotary club trains undergrads for teaching literacy workshops    BBC names Egypt as best tourism destination for 2020    WHO says new China coronavirus could spread, warns hospitals worldwide    Brain freeze: Russian firm offers path to immortality for a fee    Ethiopian Dam talks to continue in Washington on Wednesday : Ministry    Mission Africa continues    Egyptian sports in 2020: challenges and opportunities    Tough Mudder obstacle course race takes place for first time in Egypt    NBE studies establishment of rowing club in Cairo    Egypt's Zamalek, Smouha presidents hit with disciplinary sanctions by EFA    Egypt's President Sisi pardons some prisoners on 25 Jan. Revolution anniversary    Egypt's Sami Anan released after near two-year detention    Liverpool's Mohamed Salah optimistic to see Egypt at 2022 World Cup    







Thank you for reporting!
This image will be automatically disabled when it gets reported by several people.





Half of lymphoma patients alive three years after new cell therapy treatment: Study
Published in Ahram Online on 08 - 12 - 2019

Out of 101 patients teated with Yescarta for an aggressive blood cancer known as refractory large B-cell lymphoma in the study, 47 were still alive at least three years later, the data presented at the American Society of Hematology meeting in Orlando showed.
“We are delivering towards our goal of potentially life-saving therapy for many patients who previously faced limited treatment options,” Christi Shaw, chief executive of Gilead's Kite unit, said in a statement. Gilead bought Kite in 2017 for $12 billion to acquire Yescarta.
Yescarta belongs to a new class of cancer treatments called CAR-T therapy, seen as potentially revolutionary due to their promise of long-term survival with a one-time treatment for certain deadly blood cancers, such as relapsed or refractory large B-cell lymphomas.
The treatment is made by harvesting T-cells from a patient's own immune system. They are then engineered to more efficiently recognize and attack the cancer cells before being infused back into the patient.
Yescarta competes with Kymriah from Novartis AG, while several companies also are developing CAR-T treatments, including some that aim to be off-the-shelf rather than patient specific.
Gilead also reported that steroids given to one group of patients helped reduce the risk of a serious complication associated with CAR T therapy called cytokine release syndrome (CRS), which can cause a range of dangerous symptoms including fever and neurological problems.
“Early steroid intervention has the potential to reduce the rate of severe CRS and neurologic events while appearing to maintain comparably impressive efficacy for Yescarta,” Dr. Max Topp, a researcher from University Hospital of Wuerzburg, Germany who worked on the study, said in a statement.


Clic here to read the story from its source.